Vaccine
development
service

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

• Avacc 3 has significant advantages over existing whooping cough vaccines
• Second major OMV platform licensing agreement with pharmaceutical company
• Over 24 million cases of whooping cough per year world-wide

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive…

• Data published in the prestigious journal ACS Central Science of the American Chemical Society
• Preclinical and clinical batches complying with ICH guidelines and WHO recommendations
• Phase I clinical study showed vaccine was safe and well tolerated
• Phase II clinical studies ongoing in endemic countries

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine Bilthoven, the Netherlands, 5 January 2022 – Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today…

• Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
• No use of mRNA or vector technology
• Better and direct immunization of mucosa against multiple corona viruses
• Intravacc focuses on preclinical and process development research and GMP vaccine production
• Financing of clinical trial study made possible in part by Dutch governmental body Top Consortium for Knowledge and Innovation (TKI)